WO2008096811A1 - 弱毒化マイナス鎖rnaウイルス - Google Patents

弱毒化マイナス鎖rnaウイルス Download PDF

Info

Publication number
WO2008096811A1
WO2008096811A1 PCT/JP2008/052016 JP2008052016W WO2008096811A1 WO 2008096811 A1 WO2008096811 A1 WO 2008096811A1 JP 2008052016 W JP2008052016 W JP 2008052016W WO 2008096811 A1 WO2008096811 A1 WO 2008096811A1
Authority
WO
WIPO (PCT)
Prior art keywords
stranded rna
rna virus
virus
genome
found
Prior art date
Application number
PCT/JP2008/052016
Other languages
English (en)
French (fr)
Inventor
Mariko Yoshizaki
Makoto Inoue
Mamoru Hasegawa
Original Assignee
Dnavec Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Corporation filed Critical Dnavec Corporation
Priority to US12/526,211 priority Critical patent/US20100323428A1/en
Priority to JP2008557149A priority patent/JPWO2008096811A1/ja
Priority to CA002677659A priority patent/CA2677659A1/en
Priority to EP08710906A priority patent/EP2123755A1/en
Publication of WO2008096811A1 publication Critical patent/WO2008096811A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation

Abstract

　本発明は、弱毒化しているマイナス鎖ＲＮＡウイルスを提供することを課題とする。本発明者らは、センダイウイルスのＬ蛋白質のアミノ酸配列における１２１４番目のアミノ酸の変異（Ｙ１２１４Ｆ）が、ウイルスのゲノム複製活性および／または転写活性を抑制することを見出した。またウイルスゲノムからのある特定の遺伝子を欠失させることで、従来に比べ更に細胞傷害性や免疫反応の軽減を図れることを見出し、本発明を完成させた。
PCT/JP2008/052016 2007-02-07 2008-02-07 弱毒化マイナス鎖rnaウイルス WO2008096811A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/526,211 US20100323428A1 (en) 2007-02-07 2008-02-07 Attenuated minus-stranded rna virus
JP2008557149A JPWO2008096811A1 (ja) 2007-02-07 2008-02-07 弱毒化マイナス鎖ｒｎａウイルス
CA002677659A CA2677659A1 (en) 2007-02-07 2008-02-07 Attenuated minus-stranded rna virus
EP08710906A EP2123755A1 (en) 2007-02-07 2008-02-07 Attenuated minus-stranded rna virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-027520 2007-02-07
JP2007027520 2007-02-07

Publications (1)

Publication Number Publication Date
WO2008096811A1 true WO2008096811A1 (ja) 2008-08-14

Family

ID=39681715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052016 WO2008096811A1 (ja) 2007-02-07 2008-02-07 弱毒化マイナス鎖rnaウイルス

Country Status (7)

Country Link
US (1) US20100323428A1 (ja)
EP (1) EP2123755A1 (ja)
JP (1) JPWO2008096811A1 (ja)
KR (1) KR20090114431A (ja)
CN (1) CN101646768A (ja)
CA (1) CA2677659A1 (ja)
WO (1) WO2008096811A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008054A1 (ja) 2008-07-16 2010-01-21 ディナベック株式会社 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法
JP2011250798A (ja) * 2008-11-05 2011-12-15 Merck Sharp & Dohme Corp 生弱毒化呼吸器合胞体ウイルス
JP2014512804A (ja) * 2011-02-25 2014-05-29 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 組換え流行性耳下腺炎ワクチン
US20140249212A1 (en) * 2011-09-27 2014-09-04 Yale University Compositions and Methods for Transient Expression of Recombinant RNA

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2702159T3 (pl) * 2011-04-28 2019-03-29 St. Jude Children's Research Hospital Szczepionka i wektor obrazowania zmodyfikowanego wirusa Sendai
CN102590068B (zh) * 2012-03-08 2015-04-01 南开大学 基于流式细胞术快速定量检测淡水环境中总病毒的方法
CN103525777B (zh) * 2013-07-01 2016-05-18 中国农业科学院兰州兽医研究所 Vii型新城疫病毒l基因突变的减毒疫苗株及其制备方法

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6230752A (ja) 1985-04-15 1987-02-09 ステパン　カンパニ− アシルオキシベンゼンスルホネ−トの製造法
JPS6230753A (ja) 1985-07-16 1987-02-09 ダブリユ−・ア−ル・グレイス・アンド・カンパニ− メルカプトカルボン酸を含むチオエ−テル及びその製造法
JPS6233879A (ja) 1985-04-25 1987-02-13 三洋化成工業株式会社 合成繊維の親水化処理剤
JPH03168087A (ja) 1989-11-28 1991-07-19 Chemo Sero Therapeut Res Inst 新規発現ベクター
WO1997016539A1 (fr) 1995-11-01 1997-05-09 Dnavec Research Inc. Virus sendai recombinant
WO1997016538A1 (fr) 1995-10-31 1997-05-09 Dnavec Research Inc. Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome
WO1997032010A1 (fr) 1996-02-29 1997-09-04 Takara Shuzo Co., Ltd. Procede pour la purification et l'elimination de virus
WO2000061737A2 (en) * 1999-04-13 2000-10-19 The Government Of The United States Of America Represented By The Department Of Health And Human Services Production of attenuated negative stranded rna virus vaccines
WO2000070055A1 (fr) 1999-05-18 2000-11-23 Dnavec Research Inc. Ribonucleoproteine derivee d'un paramyxovirus
WO2000070070A1 (fr) 1999-05-18 2000-11-23 Dnavec Research Inc. Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
WO2001018223A1 (fr) 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
WO2003025570A1 (en) 2001-09-18 2003-03-27 Dnavec Research Inc. Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same
WO2005071092A1 (ja) 2004-01-22 2005-08-04 Dnavec Research Inc. サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法
WO2005071085A1 (ja) 2004-01-22 2005-08-04 Dnavec Research Inc. ウイルスベクターの製造方法
JP2006325531A (ja) * 2005-05-27 2006-12-07 National Institute Of Advanced Industrial & Technology センダイウイルス温度感受性株由来のウイルスベクター
WO2007044483A2 (en) * 2005-10-07 2007-04-19 President And Fellows Of Harvard College Attenuated vaccines for non-segmented negative sense rna viruses
WO2008007581A1 (fr) * 2006-07-13 2008-01-17 Dnavec Corporation Vecteur de virus paramyxoviridae non répliquant

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6230752A (ja) 1985-04-15 1987-02-09 ステパン　カンパニ− アシルオキシベンゼンスルホネ−トの製造法
JPS6233879A (ja) 1985-04-25 1987-02-13 三洋化成工業株式会社 合成繊維の親水化処理剤
JPS6230753A (ja) 1985-07-16 1987-02-09 ダブリユ−・ア−ル・グレイス・アンド・カンパニ− メルカプトカルボン酸を含むチオエ−テル及びその製造法
JPH03168087A (ja) 1989-11-28 1991-07-19 Chemo Sero Therapeut Res Inst 新規発現ベクター
WO1997016538A1 (fr) 1995-10-31 1997-05-09 Dnavec Research Inc. Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome
WO1997016539A1 (fr) 1995-11-01 1997-05-09 Dnavec Research Inc. Virus sendai recombinant
WO1997032010A1 (fr) 1996-02-29 1997-09-04 Takara Shuzo Co., Ltd. Procede pour la purification et l'elimination de virus
WO2000061737A2 (en) * 1999-04-13 2000-10-19 The Government Of The United States Of America Represented By The Department Of Health And Human Services Production of attenuated negative stranded rna virus vaccines
WO2000070055A1 (fr) 1999-05-18 2000-11-23 Dnavec Research Inc. Ribonucleoproteine derivee d'un paramyxovirus
WO2000070070A1 (fr) 1999-05-18 2000-11-23 Dnavec Research Inc. Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
WO2001004272A1 (en) 1999-07-09 2001-01-18 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
WO2001018223A1 (fr) 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
WO2003025570A1 (en) 2001-09-18 2003-03-27 Dnavec Research Inc. Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same
WO2005071092A1 (ja) 2004-01-22 2005-08-04 Dnavec Research Inc. サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法
WO2005071085A1 (ja) 2004-01-22 2005-08-04 Dnavec Research Inc. ウイルスベクターの製造方法
JP2006325531A (ja) * 2005-05-27 2006-12-07 National Institute Of Advanced Industrial & Technology センダイウイルス温度感受性株由来のウイルスベクター
WO2007044483A2 (en) * 2005-10-07 2007-04-19 President And Fellows Of Harvard College Attenuated vaccines for non-segmented negative sense rna viruses
WO2008007581A1 (fr) * 2006-07-13 2008-01-17 Dnavec Corporation Vecteur de virus paramyxoviridae non répliquant

Non-Patent Citations (104)

* Cited by examiner, † Cited by third party
Title
"State-of-the-Art Technology Protocol in Neuroscience Research III, Molecular Neuron Physiology", 1993, pages: 153 - 172
ADACHI, A.; KANDA, T.; SHIBUTA, H.: "Isolation and characterization of temperature-sensitive mutants of Sendai virus", MICROBIOL IMMUNOL, vol. 24, 1980, pages 1053 - 1068
ALTSCHUL SF ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403
ANJEANETTE ROBERT ET AL., VIROLOGY, vol. 247, 1998, pages 1 - 6
ARAI, T. ET AL., J. VIROL, vol. 72, 1998, pages 1115 - 1121
ARAI, T. ET AL., J. VIROLOGY, vol. 72, 1998, pages 1115 - 1121
BARON, M. D.; BARRETT, T., J. VIROL., vol. 71, 1997, pages 1265 - 1271
BARTLETT E.J. ET AL.: "Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys", VACCINE, vol. 23, no. 38, 2005, pages 4631 - 4646, XP005021726 *
BARTLETT, E. J. ET AL.: "Human parainfluenza virus type I (HPIV 1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys", VACCINE, vol. 23, 2005, pages 4631 - 4646
BASTIEN, N. ET AL.: "Human metapneumovirus infection in the Canadian population", J CLIN MICROBIOL, vol. 41, 2003, pages 4642 - 4646
BIACCHESI, S. ET AL.: "Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate", J VIROL, vol. 78, 2004, pages 12877 - 12887, XP002318326, DOI: doi:10.1128/JVI.78.23.12877-12887.2004
BOIVIN, G. ET AL.: "Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups", J INFECT DIS, vol. 186, 2002, pages 1330 - 1334, XP002285869, DOI: doi:10.1086/344319
BRIDGEN, A.; ELLIOTT, R. M., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 15400 - 15404
BUKREYEV, A. ET AL.: "Nonsegmented negative-strand viruses as vaccine vectors", J VIROL, vol. 80, 2006, pages 10293 - 10306, XP008109018, DOI: doi:10.1128/JVI.00919-06
CAO, J. X. ET AL.: "Passage of Japanese encephalitis virus in HeLa cells results in attenuation of virulence in mice", J GEN VIROL, vol. 76, 1995, pages 2757 - 2764, XP002910403
CHANDRIKA, R. ET AL., VIROLOGY, vol. 213, 1995, pages 352 - 363
CORTESE C.K. ET AL.: "Mutations in domain V of the Sendai virus L polymerase protein uncouple transcription and replication and differentially affect replication in vitro and in vivo", VIROLOGY, vol. 277, no. 2, 2000, pages 387 - 396, XP004435822 *
CORTESE, C. K. ET AL., VIROLOGY, vol. 277, 2000, pages 387 - 396
DECKER, T.; LOHMANN-MATTHES, M. L., J IMMUNOL METHODS, vol. 115, 1988, pages 61 - 69
DENG, W. P.; NICKOLOFF, J. A., ANAL. BIOCHEM., vol. 200, 1992, pages 81
DURBIN, A. P. ET AL., VIROLOGY, vol. 235, 1997, pages 323 - 332
FELLER J.A. ET AL.: "Comparison of identical temperature-sensitive mutations in the L polymerase proteins of sendai and parainfluenza3 viruses", VIROLOGY, vol. 276, no. 1, 2000, pages 190 - 201, XP004436220 *
FELLER, J. A. ET AL., VIROLOGY, vol. 269, 2000, pages 426 - 439
FERRON, F. ET AL., TRENDS BIOCHEM SCI, vol. 27, 2002, pages 222 - 224
FUERST, T.R. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 8122 - 8126
FUJII Y. ET AL.: "Identification of mutations associated with attenuation of virulence of a field Sendai virus isolate by egg passage", VIRUS GENES, vol. 25, no. 2, 2002, pages 189 - 193, XP003023707 *
FUJITA, K.; SILVER, J.; PEDEN, K.: "Changes in both gp 120 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type 1", J VIROL, vol. 66, 1992, pages 4445 - 4451
GARCIN, D., EMBO J., vol. 14, 1995, pages 6087 - 6094
GOUGH, N. M., ANAL BIOCHEM, vol. 173, 1988, pages 93 - 95
GRAFF, J. ET AL.: "Mutational events in consecutive passages of hepatitis A virus strain GBM during cell culture adaptation", VIROLOGY, vol. 204, 1994, pages 60 - 68, XP000198355, DOI: doi:10.1006/viro.1994.1510
GUBBAY, O. ET AL., J GEN VIROL, vol. 82, 2001, pages 2895 - 2903
HALLER, A. A. ET AL., VIROLOGY, vol. 288, 2001, pages 342 - 350
HALLER, A. A. ET AL.: "A single amino acid substitution in the viral polymerase creates a temperature-sensitive and attenuated recombinant bovine parainfluenza virus type 3", VIROLOGY, vol. 288, 2001, pages 342 - 350
HASAN, M. K. ET AL., J. GEN. VIROL., vol. 78, 1997, pages 2813 - 2820
HASAN, M. K. ET AL., J. GENERAL VIROLOGY, vol. 78, 1997, pages 2813 - 2820
HAUGHT, C. ET AL., BIOTECHNIQUES, vol. 16, no. 1, 1994, pages 47 - 48
HIRATA, T., J. VIROL METHODS, vol. 104, 2002, pages 125 - 133
HORIKAMI S.M. ET AL.: "Alternative amino acids at a single site in the Sendai virus L protein produce multiple defects in RNA synthesis in vitro", VIROLOGY, vol. 211, no. 2, 1995, pages 577 - 582, XP008112782 *
HORIKAMI, S. M.; MOYER, S. A., VIROLOGY, vol. 211, 1995, pages 577 - 582
INOUE M. ET AL.: "M,F,HN Envelope Kanren 3 Idenshi Subete o Kesshitsu shita Sendai Virus Vector Sakushutsu no Seiko to Sono Seino Hyoka", DAI 52 KAI THE JAPANESE SOCIETY OF VIROLOGY GAKUJUTSU SHUKAI PROGRAM SHOROKUSHU, 2004, pages 149, XP003025806 *
INOUE M., J GENE MED., vol. 6, 2004, pages 1069 - 1081
INOUE, K. ET AL., J. VIROL. METHODS, vol. 107, 2003, pages 229 - 236
INOUE, M. ET AL., J GENE MED, vol. 6, 2004, pages 1069 - 1081
INOUE, M. ET AL., J VIROL, vol. 77, 2003, pages 6419 - 6429
INOUE, M. ET AL., J. VIROL., vol. 77, 2003, pages 6419 - 6429
INOUE, M. ET AL.: "Recombinant Sendai virus vectors deleted in both the matrix and the fusion genes: efficient gene transfer with preferable properties", J GENE MED, vol. 6, 2004, pages 1069 - 1081, XP009077374, DOI: doi:10.1002/jgm.597
INOUE, M., J.VIROL., vol. 77, 2003, pages 6419 - 6429
ITO M. ET AL.: "Early stage of establishment of persistent Sendai virus infection: unstable dynamic phase and then selection of viruses which are tightly cell associated, temperature sensitive, and capable of establishing persistent infection", J. VIROL., vol. 78, no. 21, 2004, pages 11939 - 11951, XP008112006 *
ITOH M. ET AL.: "Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells", J. GEN. VIROL., vol. 78, no. PART 12, 1997, pages 3207 - 3215, XP008111764 *
ITOH, M. ET AL.: "Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells", J GEN VIROL, vol. 78, 1997, pages 3207 - 3215, XP008111764
J. VIROL., vol. 68, 1994, pages 8413 - 8417
J. VIROLOGY, vol. 39, 1981, pages 519 - 528
JOURNAL OF VIROLOGY, vol. 67, no. 8, 1993, pages 4822 - 4830
KANDA, T.; SHIBUTA, H.: "Restricted viral RNA synthesis in establishment of persistent infection in Vero cells with a Sendai virus mutant", MICROBIOL IMMUNOL, vol. 26, 1982, pages 1045 - 1055
KARLIN S; ALTSCHUL SF, PROC. NATL. ACAD SCI. USA, vol. 90, 1993, pages 5873 - 5877
KARLIN S; ALTSCHUL SF, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268
KATO, A. ET AL., EMBO J., vol. 16, 1997, pages 578 - 587
KATO, A. ET AL., GENES CELLS, vol. 1, 1996, pages 569 - 579
KATO, A. ET AL., J. VIROL., vol. 71, 1997, pages 7266 - 7272
KRIEG, P.A.; MELTON, D.A., METHODS ENZYMOL., vol. 155, 1987, pages 397 - 15
LAWSON, N. D. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, pages 4477 - 4481
LI, H. O. ET AL., J VIROL, vol. 74, 2000, pages 6564 - 6569
LI, H. O. ET AL.: "A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression", J VIROL, vol. 74, 2000, pages 6564 - 6569, XP002960448, DOI: doi:10.1128/JVI.74.14.6564-6569.2000
LI, H.-O. ET AL., J. VIROL., vol. 74, 2000, pages 6564 - 6569
LI, H.-O. ET AL., J. VIROL., vol. 74, no. 14, 2000, pages 6564 - 6569
LI, H.-O. ET AL., J.VIROL., vol. 74, 2000, pages 6564 - 6569
MALUR, A. G. ET AL., GENE EXPR, vol. 10, 2002, pages 93 - 100
MCAULIFFE, J. M. ET AL., J VIROL, vol. 78, 2004, pages 2029 - 2036
MCAULIFFE, J. M. ET AL.: "Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro", J VIROL, vol. 78, 2004, pages 2029 - 2036, XP002537725, DOI: doi:10.1128/JVI.78.4.2029-2036.2004
MILLIGAN, J.F. ET AL., NUCLEIC ACIDS RES., vol. 15, 1987, pages 8783 - 798
MURPHY, B. R.; COLLINS, P. L., J CLIN INVEST, vol. 110, 2002, pages 21 - 27
NAGATA, I. ET AL.: "Temperature-sensitive phenomenon of viral maturation observed in BHK cells persistently infected with HVJ", VIROLOGY, vol. 49, 1972, pages 453 - 461, XP023289859, DOI: doi:10.1016/0042-6822(72)90497-7
NAKANO, 2003, pages 147
NEWMAN J.T ET AL.: "Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses", J. VIROL., vol. 78, no. 4, 2004, pages 2017 - 2028, XP002472057 *
NEWMAN, J. T. ET AL.: "Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses", J VIROL, vol. 78, 2004, pages 2017 - 2028, XP002472057, DOI: doi:10.1128/JVI.78.4.2017-2028.2004
NISHIO, M. ET AL., VIROLOGY, vol. 329, 2004, pages 289 - 301
NISHIO, M. ET AL.: "Characterization of Sendai virus persistently infected L929 cells and Sendai virus pi strain: recombinant Sendai viruses having Mpi protein shows lower cytotoxicity and are incapable of establishing persistent infection", VIROLOGY, vol. 314, 2003, pages 110 - 124, XP004457931, DOI: doi:10.1016/S0042-6822(03)00404-5
NISHIO, M. ET AL.: "Recombinant Sendai viruses with L1618V mutation in their L polymerase protein establish persistent infection, but not temperature sensitivity", VIROLOGY, vol. 329, 2004, pages 289 - 301, XP004613860
NIWA, H. ET AL., GENE, vol. 108, 1991, pages 193 - 199
POKROVSKAYA, I.D.; GUREVICH, V.V., ANAL. BIOCHEM., vol. 220, 1994, pages 420 - 23
RADECKE, F. ET AL., EMBO J., vol. 14, 1995, pages 5773 - 5784
SAITO ET AL., NUCL. ACIDS RES., vol. 23, 1995, pages 3816 - 3821
SAWYER, L. S. ET AL.: "Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated", J VIROL, vol. 68, 1994, pages 1342 - 1349
SCHNELL, M. J.; CONZELMANN, K. K., VIROLOGY, vol. 214, 1995, pages 522 - 530
SCHNELL. M. J. ET AL., EMBO J., vol. 13, 1994, pages 4195 - 4203
SKIADOPOULOS, M. H. ET AL., J VIROL, vol. 73, 1999, pages 1374 - 1381
SKIADOPOULOS, M. H. ET AL.: "Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine", J VIROL, vol. 73, 1999, pages 1374 - 1381, XP000943239
SMALLWOOD S. ET AL.: "Different substitutions at conserved amino acids in domains II and III in the Sendai L RNA polymerase protein inactivate viral RNA synthesis", VIROLOGY, vol. 304, no. 1, 2002, pages 135 - 145, XP008112038 *
SMALLWOOD, S. ET AL., VIROLOGY, vol. 262, 1999, pages 375 - 383
SMALLWOOD, S. ET AL., VIROLOGY, vol. 304, 2002, pages 135 - 145
SMALLWOOD, S. ET AL., VIROLOGY, vol. 304, 2002, pages 235 - 245
TASHIRO, M.: "Virus Experiment Protocol", 1995, MEDICAL VIEW CO., LTD., pages: 68 - 73
THOMPSON JD ET AL., NUCLEIC ACIDS RES, vol. 22, 1994, pages 4673 - 4680
TOKUSUMI, T. ET AL., VIRUS RES, vol. 86, 2002, pages 33 - 38
TOKUSUMI, T. ET AL., VIRUS RES., vol. 86, 2002, pages 33 - 38
WHELAN, S. P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 8388 - 8392
WHITEHEAD, S. S. ET AL.: "Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees", J VIROL, vol. 73, 1999, pages 3438 - 3442, XP002154720
YOSHIDA, T. ET AL.: "Studies on the role of M protein in virus assembly using a ts mutant of HVJ (Sendai virus)", VIROLOGY, vol. 92, 1979, pages 139 - 154, XP023049964, DOI: doi:10.1016/0042-6822(79)90220-4
YOSHITAKE, J. ET AL., J VIROL, vol. 78, 2004, pages 8709 - 8719
YOSHIZAKI, M. ET AL.: "Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity", J GENE MED, vol. 8, 2006, pages 1151 - 1159, XP055048809, DOI: doi:10.1002/jgm.938
YU, D. ET AL., GENES CELLS, vol. 2, 1997, pages 457 - 466
YURCHAK, L. K. ET AL., J BIOL CHEM, vol. 271, 1996, pages 12549 - 12554
ZHU, L., METHODS MOL. BIOL., vol. 57, 1995, pages 13 - 29
ZHU, L.; HOLTZ, A., METHODS MOL. BIOL., vol. 57, 1996, pages 119 - 137

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695445B2 (en) 2008-07-16 2017-07-04 Id Pharma Co., Ltd. Method for production of reprogrammed cell using chromosomally unintegrated virus vector
US9127256B2 (en) 2008-07-16 2015-09-08 Dnavec Corporation Method for production of reprogrammed cell using chromosomally unintegrated virus vector
JP2015164434A (ja) * 2008-07-16 2015-09-17 株式会社Ｉｄファーマ 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法
EP3075850A1 (en) 2008-07-16 2016-10-05 IP Pharma Co., Ltd. Method for production of reprogrammed cell using chromosomally unintegrated virus vector
WO2010008054A1 (ja) 2008-07-16 2010-01-21 ディナベック株式会社 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法
US11136594B2 (en) 2008-07-16 2021-10-05 Id Pharma Co., Ltd. Method for production of reprogrammed cell using chromosomally unintegrated virus vector
JP2011250798A (ja) * 2008-11-05 2011-12-15 Merck Sharp & Dohme Corp 生弱毒化呼吸器合胞体ウイルス
JP2012507302A (ja) * 2008-11-05 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション 生弱毒化呼吸器合胞体ウイルス
JP2014512804A (ja) * 2011-02-25 2014-05-29 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 組換え流行性耳下腺炎ワクチン
US9649371B2 (en) 2011-02-25 2017-05-16 University Of Georgia Research Foundation, Inc. Recombinant mumps virus vaccine
US11027008B2 (en) 2011-02-25 2021-06-08 University Of Georgia Research Foundation, Inc. Recombinant mumps virus vaccine
US20140249212A1 (en) * 2011-09-27 2014-09-04 Yale University Compositions and Methods for Transient Expression of Recombinant RNA
US9951349B2 (en) * 2011-09-27 2018-04-24 Yale University Compositions and methods for transient expression of recombinant RNA

Also Published As

Publication number Publication date
US20100323428A1 (en) 2010-12-23
CA2677659A1 (en) 2008-08-14
KR20090114431A (ko) 2009-11-03
JPWO2008096811A1 (ja) 2010-05-27
CN101646768A (zh) 2010-02-10
EP2123755A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
WO2008096811A1 (ja) 弱毒化マイナス鎖rnaウイルス
EA201791343A1 (ru) Композиции и способы для конструирования вирусного генома in vitro
WO2009039248A3 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
MX2007009628A (es) Virus de acido ribonucleico en replicacion como vacunas.
WO2005042728A3 (en) Immortalized avian cell lines for virus production
WO2007098267A3 (en) Pseudoinfectious flavivirus and uses thereof
WO2010107739A3 (en) Methods and compositions of treating a flaviviridae family viral infection
WO2010021681A3 (en) Compositions and methods for treatment of viral diseases
WO2007044483A3 (en) Attenuated vaccines for non-segmented negative sense rna viruses
WO2008028661A3 (en) Potexvirus- derived replicon
WO2006136448A3 (en) Attenuated sars and use as a vaccine
WO2010042751A3 (en) Chimeric therapeutics, compositions, and methods for using same
WO2010042755A3 (en) Chimeric therapeutics, compositions, and methods for using same
WO2010090857A8 (en) Methods for amplifying hepatitis c virus nucleic acids
EP2527445A3 (en) Treatment and prevention of influenza
WO2007089732A3 (en) Improvement of levels and/or sustainability of dna-based gene expression
WO2005103254A8 (en) UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
WO2008045601A3 (en) Adenovirus-based genetic vaccines for biodefense
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection
WO2010080782A3 (en) Random homozygous gene perburbation (rhgp) with thermal assymetric interlaced (tail)-pcr
WO2007001928A3 (en) Targets for inhibiting hcv replication
EA200401362A1 (ru) Антивирусная терапия, основанная на противодействии рнк
WO2008091283A3 (en) Viral inhibitory nucleotide sequences and vaccines
WO2008139627A1 (ja) 酵母細胞を用いたインフルエンザウイルスゲノムの複製・転写系
MD3300G2 (ro) Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880009517.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710906

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008557149

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2677659

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008710906

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097018335

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12526211

Country of ref document: US